Ovaleap is a hormonal drug used in assisted reproduction treatments such as in vitro fertilisation (IVF).
Specifically said, Ovaleap contains the follicle-stimulating hormone (FSH) and is indicated for controlled ovarian stimulation and ovulation induction.
The injection of Ovaleap is easily done by using a pen which should be kept in the refrigerator.
The different sections of this article have been assembled into the following table of contents.
Ovaleap is a drug used in assisted reproduction that was firsrt authorised in Europe in September 2013.
Its active ingredient is alpha-folitropin, a gonadotropin obtained in a recombinant way in the laboratory.
This means that Ovaleap is a biosimilar medicine to the original Gonal-f.
A biosimilar medicinal product is a biological medicinal product, produced in accordance with specific requirements laid down by the European Medicines Agency with regard to quality, efficacy and safety, and which has been shown to be comparable to the reference innovative medicinal product, after the expiry of the patent.
The difference with a generic drug is that the latter are drugs that have the same qualitative and quantitative composition in active ingredients and the same pharmaceutical form as the original, whereas biosimilar refers to products synthesised in a biological form that are not identical to the original.
The function of the hormone folitropin alpha is to cause multiple and controlled follicular development in the woman's ovaries. In this way, it is possible to obtain several mature eggs that will later be extracted and fertilised in the IVF laboratory.
In the case of artificial insemination (AI), only one or two mature follicles are needed to prevent multiple pregnancy. Therefore, the gynecologist will advise the woman to take a lower dose of Ovaleap.
The Ovaleap presentation format is a multidose cartridge that already comes with the solution ready to be injected with the device known as Ovaleap Pen. Additionally, the medicine box also contains disposable needles.
Depending on the hormone dose of the cartridge, there are 3 types of Ovaleap presentation:
The other components of Ovaleap are the following: sodium dihydrogen phosphate dihydrate, sodium hydroxide, mannitol, methionine, polysorbate 20, benzyl alcohol, benzalkonium chloride and water for the injectable preparations.
Ovaleap is indicated for ovarian stimulation in assisted reproduction technology, as well as in men who do not produce FSH to help sperm production.
In terms of efficiency, Ovaleap is similar to other types of gonadotropins as demonstrated by the studies presented for demonstration of equivalence.
However, some studies point to a greater cost-effectiveness of the reference product Gonal-f with respect to its biosimilars, although more data would be needed to confirm this finding.
Ovaleap is administered by subcutaneous injection with a pen (the Ovaleap Pen) to which the cartridge with the medicine and the disposable needle are attached.
The Ovaleap Pen must be purchased separately, as it does not come in the box of the medication. Normally, it is the clinic itself that provides the patient with this device for free.
Next, let's look at the steps to follow for the Ovaleap injection.
The Ovaleap pen comes in a large green case. The following instructions must be followed to attach the cartridge with the medication to the Ovaleap Pen:
After all this has been done, you will be able to see one or two drops of the medicine come out of the needle and then the Ovaleap Pen will be ready for the injection.
After the preparation of the Ovaleap Pen, it is necessary to continue with the administration of the drug in the woman's abdomen:
The use of Ovaleap can lead to more or less frequent adverse reactions of varying severity.
The most common side effects of Ovaleap in women are the following:
Other less frequent or very rare adverse reactions are thromboembolism, anaphylactic reactions, worsening of asthma or severe OHS.
For men using Ovaleap to treat hypogonadotropic hypogonadism, they may also experience frequent side effects such as acne, weight gain, gynecomastia or varicocele.
Other more rare adverse reactions are worsening of asthma and hypersensitivity reactions such as shock and anaphylactic reactions.
Assisted procreation, as any other medical treatment, requires that you rely on the professionalism of the doctors and staff of the clinic you choose. Obviously, each clinic is different. Get now your Fertility Report, which will select several clinics for you out of the pool of clinics that meet our strict quality criteria. Moreover, it will offer you a comparison between the fees and conditions each clinic offers in order for you to make a well informed choice.
Ovaleap's main advantage is its administration device.
In a recent study, 402 patients from different countries were surveyed to evaluate what they considered to be the most important characteristics of devices for self-administration of medication in assisted reproduction treatments. Of the 6 most valued characteristics, Ovaleap has the device with the highest number of them, 5 in total (type of device: multi-dose pen, with dial-back function, possibility of increasing the dose in small amounts, release button for injection and visibility of the remaining medication in the cartridge).
Only the Puregon device outperformed it in one feature, the daily injection volume, being 0.18ml while with Ovaleap it is 0.25ml.
The price of the Ovaleap drug depends on the dose purchased. For example, Ovaleap 300 costs £100, while Ovaleap 450 is priced at £150. Finally, the drug with the highest hormone dose, Ovaleap 900, costs £300.
Ovaleap is a medicine used in assisted reproduction treatments in the following cases:
Ovaleap must be kept in the refrigerator in its original packaging to protect it from light. Before opening and during its 2 year validity period, Ovaleap can be taken out of the fridge, without being refrigerated again, for up to 3 months. In this case, the storage temperature must not exceed 25°C.
Once Ovaleap has been opened after its first administration, the cartridge must be kept inside the pen and stored for a maximum period of 28 days at a temperature below 25ºC. However, it is more advisable to keep the pen with the medication in the refrigerator at a temperature between 2 and 8ºC until it is used again.
If you would like more information on the drugs used in assisted reproduction treatments, do not miss out on the following article: What medications are used for ovarian stimulation?
We have mentioned that Ovaleap is a biosimilar drug to Gonal-f. If you want to read more about this drug, you can access the following post: Gonal-f injection for IVF- uses, dosage, price & side effects.
We make a great effort to provide you with the highest quality information.
🙏 Please share this article if you liked it. 💜💜 You help us continue!
Spanish Agency of Medicines and Health Products. CIMA. Ovaleap 300 UI / 0.5 ml injectable solution. REGISTER No: 113871001. Brochure: user information. (Link)
Spanish Agency of Medicines and Health Products. CIMA. Ovaleap 450 UI / 0,75 ml injectable solution. REGISTER No: 113871002. Brochure: user information. (Link)
Agencia Española de Medicamentos y Productos Sanitarios. CIMA. Ovaleap 900 UI / 1,5 ml solución inyectable. (ver)
European Medicines Agency. Ovaleap: EPAR - Product Information. Última actualización: 13/12/2018 (Link)
Gizzo S. A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain. J Med Econ. 2018 Nov;21(11):1096-1101.
Zitoun P. Analysis of patient and nurse preferences for self-administered FSH injection devices in select European markets. Int J Womens Health. 2019 Jan 7;11:11-21.